140 related articles for article (PubMed ID: 9291246)
1. Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.
White HD
Am J Cardiol; 1997 Aug; 80(4A):44B-48B. PubMed ID: 9291246
[No Abstract] [Full Text] [Related]
2. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Ramanathan A; Kleiman NS
Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
[No Abstract] [Full Text] [Related]
3. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
4. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Berkowitz SD
Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Steinhubl SR; Moliterno DJ
Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567
[TBL] [Abstract][Full Text] [Related]
6. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
7. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
8. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
Scheller B; Hennen B; Böhm M; Nickenig G
Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
[No Abstract] [Full Text] [Related]
9. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
[No Abstract] [Full Text] [Related]
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
12. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
Teirstein PS; Kao J; Watkins M; Tannenbaum MA; Laufer N; Chang M; Mehran R; Dangas G; Russell ME; Ellis SG; Stone GW
Am J Cardiol; 2005 Aug; 96(4):500-5. PubMed ID: 16098300
[TBL] [Abstract][Full Text] [Related]
13. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
Dobesh PP; Latham KA
Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
[TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young JJ
J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
[No Abstract] [Full Text] [Related]
15. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Popma JJ; Satler LF
J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
[TBL] [Abstract][Full Text] [Related]
16. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
[TBL] [Abstract][Full Text] [Related]
17. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
Boersma E
J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
[No Abstract] [Full Text] [Related]
19. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
[TBL] [Abstract][Full Text] [Related]
20. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
Lefkovits J; Topol EJ
Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
